| http://www.w3.org/ns/prov#value | - Another initiative advocated by FDA's Director of the Center for Drug Evaluation and Research Janet Woodcock is a richer and more accessible network of hospitals and doctors which would facilitate market entry for BTD drugs, whose developers would otherwise need to build networks of suitable patient facilities and physicians from scratch.
|
